Roxatidine versus ranitidine in the treatment of duodenal ulcers: A randomized double-blind controlled multicentre study in Singapore

Roxatidine acetate, a new H₂ receptor antagonist, was compared with ranitidine in the treatment of duodenal ulcers in a double-blind multicentre study. Eighty-four patients with endoscopically proven duodenal ulcer were randomized to receive 150 mg roxatidine acetate or 300 mg ranitidine at bedtime. Repeat endoscopy was performed after 4 weeks (25–33 days) and if the ulcer had not healed, another endoscopy was performed after a further 4 weeks of treatment. Using per protocol analysis 73.6% of ulcers treated with roxatidine healed at 4 weeks compared to 72.2% of ulcers treated with ranitidine (P=NS). The healing rates at 8 weeks were 92% with roxatidine and 83.3% with ranitidine (P=NS). Using equivalence tests, the healing rate of roxatidine was found to be equivalent to that of ranitidine within a 20% region. Roxatidine users took significantly less antacids than ranitidine users (P < 0.05). There were no significant adverse effects due to roxatidine or ranitidine. Roxatidine is a safe effective drug in the treatment of duodenal ulcers with a healing rate comparable to that of ranitidine.     

Acute urinary retention in a child due to procolpos and pyometrium

Acute urinary retention in a child is an unusual occurrence. A case of acute urinaryretention due to pyocolpos and pyometrium is presented and discussed. Emphasis is on early diagnosis and treatment by drainage to alleviate progressive obstruction of the urinary tract. Other causes of acute urinary retention in the pediatric age group are briefly outlined.     

Carcass and liver composition following acute oxytetracycline treatment of ob/ob mice

Fully mature (24-week old) C57BL/6J ob/ob mice and their lean littermates received daily oxytetracycline injections (50 or 100 mg/kg) during a 10 day period. The effects of the drug on the glucose, IRI, corticosterone levels, and on hepatic and body composition of ad libitum fed obese mice were compared with those of food-restricted and ad libitum fed lean and obese control animals. When compared with food-restricted obese mice, drug treatment led to substantial reductions of serum glucose, serum IRI, carcass fat, and hepatic lipid content, while it increased lean body mass and liver glycogen concentration. Similarly, oxytetracycline decreased body weight, and serum glucose in lean mice, but the drug had no substantial effect on circulating IRI levels or on the lipid content of carcass. A significant increase in hepatic lipid was observed in drug-treated lean mice. No effects of the drug on basal corticosterone levels were noted in either phenotype. These data support previous findings showing the effectiveness of oxytetracycline to reverse many of the metabolic abnormalities of ob/ob mice. In addition, the present results suggest that the drug acts by independently altering abnormal metabolism in many target organs, including pancreas, adipose tissue, liver, and muscle, rather than by merely reducing circulating insulin levels or by generally increasing insulin sensitivity.     

Relationship of a leukemia-associated antigen to the presence of lymphoblasts in the peripheral blood in children with acute lymphocytic leukemia

Peripheral blood samples from 57 children with newly diagnosed E- rosette-negative, surface-immunoglobulin negative acute lymphocytic leukemia (ALL) were studied for the presence of a leukemia-associated antigen (ALLA). Ficoll-Hypaque separated cells were tested using a rabbit antiserum to human null lymphoblasts and an indirect immunofluorescent assay. The percentage of ALLA-positive cells were compared to the percentage of lymphoblasts determined by differential counts of a Wright-Giemsa-stained smear of a concurrently obtained peripheral blood sample. The mean ratio of percentage of lymphoblasts to percentage of ALLA-positive cells was 0.90. However, in 13 patients, the ratio of percent of ALLA-positive cells to percent of lymphoblasts was equal to or greater than 2:1. In the blood of 6 additional children (5 newly diagnosed, 1 relapsed patient) in whom no morphologically identifiable lymphoblasts were detected. ALLA-positive cells were present (7%-49%). These results indicate that testing for ALLA-positive cells in a sensitive technique for detection of leukemic cells in children with ALLA-positive ALL.